Nakamura T, Kurashina T, Saito Y, Sumino H, Akuzawa N, Aizawa H, Sakamoto H, Ono Z, Nagai R
Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
Hypertens Res. 1998 Dec;21(4):251-7. doi: 10.1291/hypres.21.251.
We investigated the ability of the ETA receptor antagonist T-0115 and the angiotensin-converting enzyme (ACE) inhibitor imidapril hydrochloride to prevent hypertensive complications induced in rats by chronic inhibition of nitric oxide (NO). Male Wistar rats were given distilled water (control), NG-nitro-L-arginine methyl ester (L-NAME) 500 mg/l, or L-NAME plus imidapril 10 mg/l in the drinking water. In rats treated with L-NAME 500 mg/l plus T-0115, T-0115 was given in the food at a dose of 0.2 mg/g food or 0.6 mg/g food. We then collected 24-h urine samples at 2, 4, and 6 wk, obtained blood samples at 6 wk, and histologically examined the kidney and heart. L-NAME markedly reduced the levels of NO metabolites in serum and urine while increasing the tail-cuff blood pressure, the urinary albumin level (1.90+/-0.65 vs. 0.05+/-0.02 mg/d/100 g in control), and the area of the left ventricular wall (83.3+/-3.0 vs. 69.8+/-1.8 mm2 in control). The plasma renin activity was significantly higher in rats treated with L-NAME than in the control rats. The concomitant administration of T-0115 0.6 mg/g food with L-NAME ameliorated the tail-cuff pressure and the albuminuria (0.56+/-0.23 mg/d/100 g), although to a lesser extent than the changes seen with imidapril 10 mg/l. T-0115 0.6 mg/g food prevented left ventricular hypertrophy as effectively as imidapril 10 mg/l (70.8+/-1.8 with T-0115 vs. 68.3+/-2.7 mm2 with imidapril). Chronic inhibition of NO synthesis produced left ventricular hypertrophy and nephrosclerosis. Our results demonstrate that inhibition of the renin-angiotensin system morely effectively prevents nephrosclerosis than does the blockade of ETA receptors in a model of hypertension induced by chronic NO blockade. However, inhibition of the ET-1 pathway appeared to be as effective as ACE inhibitors in preventing left ventricular hypertrophy in this model.
我们研究了内皮素 A(ETA)受体拮抗剂 T - 0115 和血管紧张素转换酶(ACE)抑制剂盐酸咪达普利预防慢性抑制一氧化氮(NO)在大鼠中诱发的高血压并发症的能力。将雄性 Wistar 大鼠分为三组,分别给予蒸馏水(对照组)、500 mg/l 的 NG - 硝基 - L - 精氨酸甲酯(L - NAME),或饮用水中含 500 mg/l L - NAME 加 10 mg/l 咪达普利。对于给予 500 mg/l L - NAME 加 T - 0115 的大鼠,T - 0115 以 0.2 mg/g 食物或 0.6 mg/g 食物的剂量混入食物中。然后在第 2、4 和 6 周收集 24 小时尿液样本,在第 6 周采集血液样本,并对肾脏和心脏进行组织学检查。L - NAME 显著降低血清和尿液中 NO 代谢产物的水平,同时提高尾袖血压、尿白蛋白水平(对照组为 0.05±0.02 mg/d/100 g,L - NAME 组为 1.90±0.65 mg/d/100 g)以及左心室壁面积(对照组为 69.8±1.8 mm²,L - NAME 组为 83.3±3.0 mm²)。用 L - NAME 处理的大鼠血浆肾素活性显著高于对照大鼠。L - NAME 与 0.6 mg/g 食物剂量的 T - 0115 联合给药可改善尾袖血压和蛋白尿(0.56±0.23 mg/d/100 g),尽管改善程度小于 10 mg/l 咪达普利组。0.6 mg/g 食物剂量的 T - 0115 预防左心室肥厚的效果与 10 mg/l 咪达普利相当(T - 0115 组为 70.8±1.8,咪达普利组为 68.3±2.7 mm²)。慢性抑制 NO 合成会导致左心室肥厚和肾硬化。我们的结果表明,在慢性 NO 阻断诱导的高血压模型中,抑制肾素 - 血管紧张素系统比阻断 ETA 受体更有效地预防肾硬化。然而,在该模型中,抑制内皮素 - 1(ET - 1)途径在预防左心室肥厚方面似乎与 ACE 抑制剂同样有效。